share_log

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $62

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $62

Needham维持对revolution medicines的买入评级,将目标股价上调至62美元。
Benzinga ·  07/16 07:28

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $46 to $62.

Needham分析师Ami Fadia维持了Revolution Medicines (NASDAQ:RVMD)的买入评级,将价格目标从46美元上调至62美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发